Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q55175640 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241121000202.0 | ||
| 008 | 241121nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q55175640 | ||
| 024 | ‡a 0000-0001-9098-1364 ‡2 orcid | ||
| 024 | ‡a 35433157100 ‡2 scopus | ||
| 035 | ‡a (OCoLC)Q55175640 | ||
| 100 | 0 | ‡a Ming Yi ‡9 ast ‡9 nl ‡9 es ‡9 sl | |
| 400 | 0 | ‡a Ming Yi ‡c researcher (ORCID 0000-0001-9098-1364) ‡9 en | |
| 670 | ‡a Author's A combined proteome and microarray investigation of inorganic phosphate-induced pre-osteoblast cells. | ||
| 670 | ‡a Author's A stromal gene signature associated with inflammatory breast cancer. | ||
| 670 | ‡a Author's Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib. | ||
| 670 | ‡a Author's An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers | ||
| 670 | ‡a Author's An integrated understanding of the physiological response to elevated extracellular phosphate. | ||
| 670 | ‡a Author's Aneuploidy, oncogene amplification and epithelial to mesenchymal transition define spontaneous transformation of murine epithelial cells | ||
| 670 | ‡a Author's Detection of genome-wide polymorphisms in the AT-rich Plasmodium falciparum genome using a high-density microarray | ||
| 670 | ‡a Author's Differences in the tumor microenvironment between African-American and European-American breast cancer patients | ||
| 670 | ‡a Author's Differential Effector Engagement by Oncogenic KRAS. | ||
| 670 | ‡a Author's Erratum to: The somatic autosomal mutation matrix in cancer genomes | ||
| 670 | ‡a Author's Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease | ||
| 670 | ‡a Author's Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology | ||
| 670 | ‡a Author's Genome-wide compensatory changes accompany drug- selected mutations in the Plasmodium falciparum crt gene | ||
| 670 | ‡a Author's Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer | ||
| 670 | ‡a Author's GradientScanSurv-An exhaustive association test method for gene expression data with censored survival outcome | ||
| 670 | ‡a Author's Guanine holes are prominent targets for mutation in cancer and inherited disease | ||
| 670 | ‡a Author's High recombination rates and hotspots in a Plasmodium falciparum genetic cross | ||
| 670 | ‡a Author's IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis | ||
| 670 | ‡a Author's Increased NOS2 predicts poor survival in estrogen receptor–negative breast cancer patients | ||
| 670 | ‡a Author's Large-scale genotyping and genetic mapping in Plasmodium parasites. | ||
| 670 | ‡a Author's Long homopurine*homopyrimidine sequences are characteristic of genes expressed in brain and the pseudoautosomal region | ||
| 670 | ‡a Author's MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. | ||
| 670 | ‡a Author's MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. | ||
| 670 | ‡a Author's MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. | ||
| 670 | ‡a Author's miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. | ||
| 670 | ‡a Author's Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy | ||
| 670 | ‡a Author's MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. | ||
| 670 | ‡a Author's Non-B DB: a database of predicted non-B DNA-forming motifs in mammalian genomes | ||
| 670 | ‡a Author's Non-B DB v2.0: a database of predicted non-B DNA-forming motifs and its associated tools | ||
| 670 | ‡a Author's Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer | ||
| 670 | ‡a Author's Performance comparison of SNP detection tools with illumina exome sequencing data--an assessment using both family pedigree information and sample-matched SNP array data | ||
| 670 | ‡a Author's Searching for non-B DNA-forming motifs using nBMST (non-B DNA motif search tool) | ||
| 670 | ‡a Author's Seeking unique and common biological themes in multiple gene lists or datasets: pathway pattern extraction pipeline for pathway-level comparative analysis | ||
| 670 | ‡a Author's SLEPR: a sample-level enrichment-based pathway ranking method -- seeking biological themes through pathway-level consistency | ||
| 670 | ‡a Author's ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications | ||
| 670 | ‡a Author's The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. | ||
| 670 | ‡a Author's The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. | ||
| 670 | ‡a Author's The somatic autosomal mutation matrix in cancer genomes | ||
| 670 | ‡a Author's Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer | ||
| 670 | ‡a Author's Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes. | ||
| 670 | ‡a Author's Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers | ||
| 670 | ‡a Author's Unique microRNA molecular profiles in lung cancer diagnosis and prognosis | ||
| 670 | ‡a Author's WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data | ||
| 909 | ‡a (scopus) 35433157100 ‡9 1 | ||
| 909 | ‡a (orcid) 0000000190981364 ‡9 1 | ||
| 919 | ‡a pathwayspecificengineeredmouseallograftmodelsfunctionallyrecapitulatehumanserousepithelialovariancancer ‡A Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer ‡9 1 | ||
| 919 | ‡a performancecomparisonofsnpdetectiontoolswithilluminaexomesequencingdataanassessmentusingbothfamilypedigreeinformationandsamplematchedsnparraydata ‡A Performance comparison of SNP detection tools with illumina exome sequencing data--an assessment using both family pedigree information and sample-matched SNP array data ‡9 1 | ||
| 919 | ‡a searchingfornonbdnaformingmotifsusingnbmstnonbdnamotifsearchtool ‡A Searching for non-B DNA-forming motifs using nBMST (non-B DNA motif search tool) ‡9 1 | ||
| 919 | ‡a seekinguniqueandcommonbiologicalthemesinmultiplegenelistsordatasetspathwaypatternextractionpipelineforpathwaylevelcomparativeanalysis ‡A Seeking unique and common biological themes in multiple gene lists or datasets: pathway pattern extraction pipeline for pathway-level comparative analysis ‡9 1 | ||
| 919 | ‡a sleprasamplelevelenrichmentbasedpathwayrankingmethodseekingbiologicalthemesthroughpathwaylevelconsistency ‡A SLEPR: a sample-level enrichment-based pathway ranking method -- seeking biological themes through pathway-level consistency ‡9 1 | ||
| 919 | ‡a ssgseascorebasedrasdependencyindexesderivedfromgeneexpressiondatarevealpotentialrasaddictionmechanismswithpossibleclinicalimplications ‡A ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications ‡9 1 | ||
| 919 | ‡a cancergenomeatlasanalysispredictsmicrornafortargetingcancergrowthandvascularizationinglioblastoma ‡A The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. ‡9 1 | ||
| 919 | ‡a roleofmir31anditstargetgenesatb2incancerassociatedfibroblasts ‡A The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. ‡9 1 | ||
| 919 | ‡a somaticautosomalmutationmatrixincancergenomes ‡A The somatic autosomal mutation matrix in cancer genomes ‡9 1 | ||
| 919 | ‡a transcriptionsignaturesencodedbyultraconservedgenomicregionsinhumanprostatecancer ‡A Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer ‡9 1 | ||
| 919 | ‡a microrna1isacandidatetumorsuppressorandprognosticmarkerinhumanprostatecancer ‡A MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. ‡9 1 | ||
| 919 | ‡a longhomopurinehomopyrimidinesequencesarecharacteristicofgenesexpressedinbrainandthepseudoautosomalregion ‡A Long homopurine*homopyrimidine sequences are characteristic of genes expressed in brain and the pseudoautosomal region ‡9 1 | ||
| 919 | ‡a detectionofgenomewidepolymorphismsintheatrichplasmodiumfalciparumgenomeusingahighdensitymicroarray ‡A Detection of genome-wide polymorphisms in the AT-rich Plasmodium falciparum genome using a high-density microarray ‡9 1 | ||
| 919 | ‡a largescalegenotypingandgeneticmappinginplasmodiumparasites ‡A Large-scale genotyping and genetic mapping in Plasmodium parasites. ‡9 1 | ||
| 919 | ‡a differencesinthetumormicroenvironmentbetweenafricanamericanandeuropeanamericanbreastcancerpatients ‡A Differences in the tumor microenvironment between African-American and European-American breast cancer patients ‡9 1 | ||
| 919 | ‡a increasednos2predictspoorsurvivalinestrogenreceptornegativebreastcancerpatients ‡A Increased NOS2 predicts poor survival in estrogen receptor–negative breast cancer patients ‡9 1 | ||
| 919 | ‡a differentialeffectorengagementbyoncogenickras ‡A Differential Effector Engagement by Oncogenic KRAS. ‡9 1 | ||
| 919 | ‡a 1rmyd88signalinginkeratinocytetransformationandcarcinogenesis ‡A IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis ‡9 1 | ||
| 919 | ‡a erratumtothesomaticautosomalmutationmatrixincancergenomes ‡A Erratum to: The somatic autosomal mutation matrix in cancer genomes ‡9 1 | ||
| 919 | ‡a highrecombinationratesandhotspotsinaplasmodiumfalciparumgeneticcross ‡A High recombination rates and hotspots in a Plasmodium falciparum genetic cross ‡9 1 | ||
| 919 | ‡a evidenceforgenderspecifictranscriptionalprofilesofnigraldopamineneuronsinparkinsondisease ‡A Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease ‡9 1 | ||
| 919 | ‡a geneexpressionprofilingofsubstantianigradopamineneuronsfurtherinsightsintoparkinsonsdiseasepathology ‡A Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology ‡9 1 | ||
| 919 | ‡a guanineholesareprominenttargetsformutationincancerandinheriteddisease ‡A Guanine holes are prominent targets for mutation in cancer and inherited disease ‡9 1 | ||
| 919 | ‡a genomewidecompensatorychangesaccompanydrugselectedmutationsintheplasmodiumfalciparumcrtgene ‡A Genome-wide compensatory changes accompany drug- selected mutations in the Plasmodium falciparum crt gene ‡9 1 | ||
| 919 | ‡a genomicprofilingofmicrornaandmessengerrnarevealsderegulatedmicrornaexpressioninprostatecancer ‡A Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer ‡9 1 | ||
| 919 | ‡a gradientscansurvanexhaustiveassociationtestmethodforgeneexpressiondatawithcensoredsurvivaloutcome ‡A GradientScanSurv-An exhaustive association test method for gene expression data with censored survival outcome ‡9 1 | ||
| 919 | ‡a aneuploidyoncogeneamplificationandepithelialtomesenchymaltransitiondefinespontaneoustransformationofmurineepithelialcells ‡A Aneuploidy, oncogene amplification and epithelial to mesenchymal transition define spontaneous transformation of murine epithelial cells ‡9 1 | ||
| 919 | ‡a tumorrasgeneexpressionlevelsareinfluencedbythemutationalstatusofrasgenesandbothupstreamanddownstreamraspathwaygenes ‡A Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes. ‡9 1 | ||
| 919 | ‡a underminingglutaminolysisbolsterschemotherapywhilenrf2promoteschemoresistanceinkrasdrivenpancreaticcancers ‡A Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers ‡9 1 | ||
| 919 | ‡a uniquemicrornamolecularprofilesinlungcancerdiagnosisandprognosis ‡A Unique microRNA molecular profiles in lung cancer diagnosis and prognosis ‡9 1 | ||
| 919 | ‡a wholepathwayscopeacomprehensivepathwaybasedanalysistoolforhighthroughputdata ‡A WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data ‡9 1 | ||
| 919 | ‡a integratedunderstandingofthephysiologicalresponsetoelevatedextracellularphosphate ‡A An integrated understanding of the physiological response to elevated extracellular phosphate. ‡9 1 | ||
| 919 | ‡a microrna106b25clusterexpressionisassociatedwithearlydiseaserecurrenceandtargetscaspase7andfocaladhesioninhumanprostatecancer ‡A MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. ‡9 1 | ||
| 919 | ‡a immuneinflammationgeneexpressionsignatureinprostatetumorsofsmokers ‡A An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers ‡9 1 | ||
| 919 | ‡a microrna10binhibitionreducese2f1mediatedtranscriptionandmir1516activityinglioblastoma ‡A MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. ‡9 1 | ||
| 919 | ‡a alteredgeneexpressionprofilesdefinepathwaysincolorectalcancercelllinesaffectedbycelecoxib ‡A Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib. ‡9 1 | ||
| 919 | ‡a mir126contributestoparkinsonsdiseasebydysregulatingtheinsulinlikegrowthfactorphosphoinositide3kinasesignaling ‡A miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. ‡9 1 | ||
| 919 | ‡a stromalgenesignatureassociatedwithinflammatorybreastcancer ‡A A stromal gene signature associated with inflammatory breast cancer. ‡9 1 | ||
| 919 | ‡a murineleukemiaswithretroviralinsertionsatlmo2arepredictiveoftheleukemiasinducedinscidx1patientsfollowingretroviralgenetherapy ‡A Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy ‡9 1 | ||
| 919 | ‡a combinedproteomeandmicroarrayinvestigationofinorganicphosphateinducedpreosteoblastcells ‡A A combined proteome and microarray investigation of inorganic phosphate-induced pre-osteoblast cells. ‡9 1 | ||
| 919 | ‡a mycdrivenaccumulationof2hydroxyglutarateisassociatedwithbreastcancerprognosis ‡A MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. ‡9 1 | ||
| 919 | ‡a nonbdbadatabaseofpredictednonbdnaformingmotifsinmammaliangenomes ‡A Non-B DB: a database of predicted non-B DNA-forming motifs in mammalian genomes ‡9 1 | ||
| 919 | ‡a nonbdbv20adatabaseofpredictednonbdnaformingmotifsanditsassociatedtools ‡A Non-B DB v2.0: a database of predicted non-B DNA-forming motifs and its associated tools ‡9 1 | ||
| 996 | ‡2 DNB|1293293857 | ||
| 996 | ‡2 ISNI|0000000492183165 | ||
| 996 | ‡2 J9U|987007368404905171 | ||
| 996 | ‡2 DNB|1281038741 | ||
| 996 | ‡2 ISNI|0000000425464493 | ||
| 996 | ‡2 ISNI|000000050535653X | ||
| 996 | ‡2 LC|n 2014074481 | ||
| 996 | ‡2 DNB|1185669523 | ||
| 996 | ‡2 ISNI|0000000501037224 | ||
| 996 | ‡2 ISNI|0000000362886882 | ||
| 996 | ‡2 LC|no2020100647 | ||
| 996 | ‡2 LC|nr 94013623 | ||
| 996 | ‡2 SUDOC|154108723 | ||
| 996 | ‡2 LC|no2008099194 | ||
| 996 | ‡2 ISNI|000000046771442X | ||
| 996 | ‡2 ISNI|0000000038166816 | ||
| 996 | ‡2 PLWABN|9810687020705606 | ||
| 996 | ‡2 LC|n 2020045510 | ||
| 996 | ‡2 ISNI|0000000465096867 | ||
| 996 | ‡2 ISNI|0000000138780434 | ||
| 996 | ‡2 LC|no2024069471 | ||
| 996 | ‡2 PLWABN|9810615464205606 | ||
| 996 | ‡2 LC|no2023134572 | ||
| 996 | ‡2 J9U|987007397908605171 | ||
| 996 | ‡2 BNE|XX5327159 | ||
| 996 | ‡2 SUDOC|276640519 | ||
| 996 | ‡2 DNB|1073241351 | ||
| 996 | ‡2 NTA|339268891 | ||
| 996 | ‡2 LC|n 80088977 | ||
| 996 | ‡2 LC|nr 97030448 | ||
| 996 | ‡2 ISNI|0000000501571611 | ||
| 996 | ‡2 NTA|383074371 | ||
| 996 | ‡2 ISNI|0000000067769050 | ||
| 996 | ‡2 DNB|1043976906 | ||
| 996 | ‡2 DNB|1183016034 | ||
| 996 | ‡2 LC|n 2022019496 | ||
| 996 | ‡2 LC|n 2011014100 | ||
| 996 | ‡2 LC|n 80156913 | ||
| 996 | ‡2 LC|nr2002016920 | ||
| 996 | ‡2 ISNI|0000000117533813 | ||
| 996 | ‡2 LC|n 2010040480 | ||
| 996 | ‡2 DNB|1027021794 | ||
| 996 | ‡2 DNB|1224483871 | ||
| 996 | ‡2 LC|n 2011030078 | ||
| 996 | ‡2 ISNI|0000000074450849 | ||
| 996 | ‡2 J9U|987007324865905171 | ||
| 996 | ‡2 DNB|115744444X | ||
| 996 | ‡2 BNF|16702451 | ||
| 996 | ‡2 PLWABN|9810681019005606 | ||
| 996 | ‡2 LC|n 2017067429 | ||
| 996 | ‡2 NTA|326653473 | ||
| 996 | ‡2 BLBNB|001609228 | ||
| 996 | ‡2 ISNI|0000000027629387 | ||
| 996 | ‡2 DNB|1263862462 | ||
| 996 | ‡2 DNB|1131652002 | ||
| 996 | ‡2 J9U|987007312475605171 | ||
| 996 | ‡2 ISNI|0000000054425152 | ||
| 996 | ‡2 LC|no2003102420 | ||
| 996 | ‡2 ISNI|0000000475170215 | ||
| 996 | ‡2 ISNI|0000000480249868 | ||
| 996 | ‡2 LC|nr 95025847 | ||
| 996 | ‡2 SUDOC|194948099 | ||
| 996 | ‡2 LC|n 2013022384 | ||
| 996 | ‡2 DBC|87097992538273 | ||
| 996 | ‡2 DBC|87097969758398 | ||
| 996 | ‡2 LC|n 2018043030 | ||
| 996 | ‡2 ISNI|0000000384340055 | ||
| 996 | ‡2 DNB|1159299129 | ||
| 996 | ‡2 LC|nr 97016235 | ||
| 996 | ‡2 LC|no2023108864 | ||
| 996 | ‡2 J9U|987007411864705171 | ||
| 996 | ‡2 LC|n 80039556 | ||
| 996 | ‡2 ISNI|0000000118536127 | ||
| 996 | ‡2 ISNI|0000000024572071 | ||
| 996 | ‡2 ISNI|0000000464202146 | ||
| 996 | ‡2 LC|n 2014008930 | ||
| 996 | ‡2 LC|n 2022006210 | ||
| 996 | ‡2 DNB|1329343018 | ||
| 996 | ‡2 DBC|87097969104606 | ||
| 996 | ‡2 PLWABN|9811766132905606 | ||
| 996 | ‡2 ISNI|0000000495869082 | ||
| 996 | ‡2 DNB|1077009046 | ||
| 996 | ‡2 LC|nr2006033182 | ||
| 996 | ‡2 ISNI|0000000118367108 | ||
| 996 | ‡2 DNB|1214303862 | ||
| 996 | ‡2 ISNI|0000000050530860 | ||
| 996 | ‡2 RERO|A000179126 | ||
| 996 | ‡2 J9U|987007375965005171 | ||
| 996 | ‡2 LC|n 82049161 | ||
| 996 | ‡2 ERRR|12535813 | ||
| 996 | ‡2 NLA|000035523926 | ||
| 996 | ‡2 DNB|134242624X | ||
| 996 | ‡2 ISNI|0000000493131527 | ||
| 996 | ‡2 ISNI|0000000024127592 | ||
| 996 | ‡2 LC|no2017028326 | ||
| 996 | ‡2 LC|n 86056662 | ||
| 996 | ‡2 RERO|A017816738 | ||
| 996 | ‡2 LC|n 2006060383 | ||
| 996 | ‡2 ISNI|0000000467831546 | ||
| 996 | ‡2 ISNI|0000000464894517 | ||
| 996 | ‡2 ISNI|0000000098297308 | ||
| 996 | ‡2 LC|no2011159105 | ||
| 996 | ‡2 LC|n 2011016665 | ||
| 996 | ‡2 ISNI|0000000503712449 | ||
| 996 | ‡2 LC|n 2020002431 | ||
| 996 | ‡2 ISNI|0000000051294222 | ||
| 996 | ‡2 ISNI|0000000044506549 | ||
| 996 | ‡2 BNF|16751193 | ||
| 996 | ‡2 LC|no2016095527 | ||
| 996 | ‡2 J9U|987007339063705171 | ||
| 996 | ‡2 LC|no2023113744 | ||
| 996 | ‡2 ISNI|0000000493222517 | ||
| 996 | ‡2 DNB|1038820588 | ||
| 996 | ‡2 SUDOC|233972196 | ||
| 996 | ‡2 ISNI|0000000453070213 | ||
| 996 | ‡2 ISNI|0000000458792119 | ||
| 996 | ‡2 LC|no2014037477 | ||
| 996 | ‡2 ISNI|0000000054794687 | ||
| 996 | ‡2 ISNI|0000000367513102 | ||
| 996 | ‡2 LC|no2024002179 | ||
| 996 | ‡2 NII|DA07645194 | ||
| 996 | ‡2 J9U|987009349538705171 | ||
| 996 | ‡2 ISNI|0000000064102330 | ||
| 996 | ‡2 NTA|334568234 | ||
| 996 | ‡2 ISNI|0000000040425290 | ||
| 996 | ‡2 NII|DA02063759 | ||
| 996 | ‡2 LC|n 2011023162 | ||
| 996 | ‡2 LC|n 2018039459 | ||
| 996 | ‡2 ISNI|0000000477787390 | ||
| 996 | ‡2 DNB|140835830 | ||
| 996 | ‡2 ISNI|0000000064302711 | ||
| 996 | ‡2 ISNI|000000040261409X | ||
| 996 | ‡2 LC|n 2010019188 | ||
| 996 | ‡2 LC|no2007046695 | ||
| 996 | ‡2 LC|n 85308982 | ||
| 996 | ‡2 BNF|13619436 | ||
| 996 | ‡2 LC|n 2021066938 | ||
| 996 | ‡2 LC|n 88298960 | ||
| 996 | ‡2 ISNI|0000000052984524 | ||
| 996 | ‡2 DNB|1019246014 | ||
| 996 | ‡2 NUKAT|n 2004035251 | ||
| 996 | ‡2 ISNI|0000000064255599 | ||
| 996 | ‡2 ISNI|000000046346307X | ||
| 996 | ‡2 LC|no2003055338 | ||
| 996 | ‡2 DNB|107998559X | ||
| 996 | ‡2 ISNI|0000000509099075 | ||
| 996 | ‡2 ISNI|0000000078111879 | ||
| 996 | ‡2 LC|n 2018037453 | ||
| 996 | ‡2 DNB|1123680221 | ||
| 996 | ‡2 BNF|15022734 | ||
| 996 | ‡2 DNB|122269347X | ||
| 996 | ‡2 DNB|1215668937 | ||
| 996 | ‡2 ISNI|0000000434540638 | ||
| 996 | ‡2 LC|n 88118701 | ||
| 996 | ‡2 ISNI|0000000050472330 | ||
| 996 | ‡2 ISNI|0000000109275068 | ||
| 996 | ‡2 LC|n 2004058526 | ||
| 996 | ‡2 SUDOC|262583399 | ||
| 996 | ‡2 ISNI|0000000463436557 | ||
| 996 | ‡2 SUDOC|129839124 | ||
| 996 | ‡2 SUDOC|140039783 | ||
| 996 | ‡2 LC|nr 98036491 | ||
| 996 | ‡2 LC|nr 93010583 | ||
| 996 | ‡2 LC|n 80061667 | ||
| 996 | ‡2 ISNI|0000000114960940 | ||
| 996 | ‡2 LC|n 2010035439 | ||
| 996 | ‡2 ISNI|0000000464934953 | ||
| 996 | ‡2 ISNI|0000000052465329 | ||
| 996 | ‡2 J9U|987007407898905171 | ||
| 996 | ‡2 LC|n 2023008567 | ||
| 996 | ‡2 ISNI|0000000071286510 | ||
| 996 | ‡2 DNB|1030066752 | ||
| 996 | ‡2 LC|n 2016002102 | ||
| 996 | ‡2 DNB|120254486X | ||
| 996 | ‡2 LC|nr2001026195 | ||
| 996 | ‡2 NTA|364370203 | ||
| 996 | ‡2 NSK|000580675 | ||
| 996 | ‡2 NII|DA1095179X | ||
| 996 | ‡2 LC|no2010094494 | ||
| 996 | ‡2 DNB|1312689102 | ||
| 996 | ‡2 J9U|987007415335205171 | ||
| 996 | ‡2 ISNI|0000000403465049 | ||
| 996 | ‡2 ISNI|0000000459548361 | ||
| 996 | ‡2 NTA|375417346 | ||
| 996 | ‡2 ISNI|0000000031374751 | ||
| 996 | ‡2 LC|n 2013042038 | ||
| 996 | ‡2 BIBSYS|7068326 | ||
| 996 | ‡2 LC|n 2018004225 | ||
| 996 | ‡2 ISNI|0000000054008797 | ||
| 996 | ‡2 LC|n 2006086697 | ||
| 996 | ‡2 LC|no2008087634 | ||
| 996 | ‡2 SUDOC|232959595 | ||
| 996 | ‡2 ISNI|0000000493222461 | ||
| 996 | ‡2 LC|n 2013030882 | ||
| 996 | ‡2 LC|n 2012026476 | ||
| 996 | ‡2 ISNI|0000000447972691 | ||
| 996 | ‡2 ISNI|0000000479064102 | ||
| 996 | ‡2 LC|nr2001022998 | ||
| 996 | ‡2 ISNI|0000000054563950 | ||
| 996 | ‡2 ISNI|0000000494016600 | ||
| 996 | ‡2 LC|n 2013031682 | ||
| 996 | ‡2 LC|nr 99036528 | ||
| 996 | ‡2 ISNI|0000000424867258 | ||
| 996 | ‡2 LC|nr 94015050 | ||
| 996 | ‡2 LC|n 2014032902 | ||
| 996 | ‡2 NLA|000035730581 | ||
| 996 | ‡2 DBC|87097992538265 | ||
| 996 | ‡2 LC|n 80062825 | ||
| 996 | ‡2 ISNI|0000000505084474 | ||
| 996 | ‡2 LC|no2021128048 | ||
| 996 | ‡2 ISNI|0000000504940371 | ||
| 996 | ‡2 LC|no2021042129 | ||
| 996 | ‡2 ISNI|0000000116094951 | ||
| 996 | ‡2 LC|n 2009021201 | ||
| 996 | ‡2 LC|n 2015042371 | ||
| 996 | ‡2 ISNI|0000000513808102 | ||
| 996 | ‡2 ISNI|0000000021486792 | ||
| 996 | ‡2 LC|n 2008008354 | ||
| 996 | ‡2 ISNI|0000000492077397 | ||
| 996 | ‡2 ISNI|0000000002891215 | ||
| 996 | ‡2 LC|n 80119193 | ||
| 996 | ‡2 DNB|1143164776 | ||
| 996 | ‡2 LC|n 2009007847 | ||
| 996 | ‡2 ISNI|0000000110421069 | ||
| 996 | ‡2 ISNI|0000000430719163 | ||
| 996 | ‡2 LC|n 2019020200 | ||
| 996 | ‡2 SUDOC|262752247 | ||
| 996 | ‡2 NUKAT|n 2014139727 | ||
| 996 | ‡2 DNB|131957789X | ||
| 996 | ‡2 LC|n 2012027122 | ||
| 996 | ‡2 LC|no2006000517 | ||
| 996 | ‡2 ISNI|0000000460722865 | ||
| 996 | ‡2 LC|nr 97030439 | ||
| 996 | ‡2 ISNI|0000000497659599 | ||
| 996 | ‡2 ISNI|000000050554897X | ||
| 996 | ‡2 DNB|1279757345 | ||
| 996 | ‡2 DNB|1091094314 | ||
| 996 | ‡2 SUDOC|165451793 | ||
| 996 | ‡2 LC|n 84013479 | ||
| 996 | ‡2 ISNI|0000000460818410 | ||
| 996 | ‡2 DNB|118986465 | ||
| 996 | ‡2 DNB|1225142369 | ||
| 996 | ‡2 LIH|LNB:CU,N;=BN | ||
| 996 | ‡2 LC|n 2017017828 | ||
| 996 | ‡2 ISNI|0000000073207169 | ||
| 996 | ‡2 ISNI|0000000037122862 | ||
| 996 | ‡2 LC|n 2018040472 | ||
| 996 | ‡2 BNF|17096363 | ||
| 996 | ‡2 SELIBR|373289 | ||
| 996 | ‡2 CYT|AC000084084 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 | ||
| 998 | ‡a Ming, Yi ‡2 LC|n 87844403 ‡3 exact name |
